Explorando fronteiras terapêuticas com inovações em terapias-alvo, imunoterapia e o potencial do curcuminoide NC2603 no tratamento do câncer de mama metastático
DOI:
https://doi.org/10.34119/bjhrv8n4-155Keywords:
HER2, triplo negativo, curcuminaAbstract
O câncer de mama é uma das neoplasias mais incidentes no mundo, com elevado impacto clínico e social. A classificação molecular baseada na expressão de biomarcadores como HER2, receptores hormonais e Ki-67 tem sido fundamental para o direcionamento terapêutico e definição prognóstica. No entanto, tumores como o subtipo triplo-negativo ainda representam um desafio clínico devido à ausência de alvos moleculares definidos e à agressividade biológica. Diante disso, compostos naturais com potencial antitumoral têm ganhado destaque, especialmente a curcumina e seus análogos sintéticos. Este estudo revisou os efeitos do análogo NC2603 em linhagens celulares de câncer de mama MCF-7 (luminal A), BT-20 (triplo-negativo) e HaCaT (não tumoral), comparando-os à doxorrubicina. Os resultados indicaram que o NC2603 induziu parada do ciclo celular em G1, inibiu a expressão de ESR1, MKI67 e PCNA, e promoveu a indução de CDKN1A e GADD45A, genes envolvidos na resposta ao estresse celular e controle do ciclo celular. Além disso, demonstrou menor toxicidade em células não tumorais. Em comparação com a doxorrubicina, apresentou maior seletividade tumoral. Tais achados sugerem que o NC2603 é um candidato promissor para terapias adjuvantes no câncer de mama, sobretudo em subtipos resistentes, reforçando a importância da pesquisa com derivados naturais no desenvolvimento de novas abordagens oncológicas.
References
Aitelhaj M, Lkhoyaali S, Rais G, Boutayeb S, Errihani H. First line chemotherapy plus trastuzumab in metastatic breast cancer HER2 positive - Observational institutional study. Pan Afr Med J. 2016 Aug 24;24:324. doi: 10.11604/pamj.2016.24.324.4058. PMID: 28154679; PMCID: PMC5267845.
AMERICAN CANCER SOCIETY. Breast cancer: detailed guide. Atlanta: ACS, 2018. Disponível em: https://www.cancer.org. Acesso em: 3 jul. 2025.
Babcock B, Rodrigues M, Kearns D, Solomon N, Reeves ME, Senthil M, Garberoglio CA, Namm JP. Improved Survival with Immunotherapy but Lack of Synergistic Effect with Radiation for Stage IV Melanoma of the Head and Neck. Am Surg. 2019 Oct 1;85(10):1118-1124. PMID: 31657306
BANYAL, A.; TIWARI, S.; SHARMA, A.; CHANANA, I.; PATEL, S. K. S.; KULSHRESTHA, S.; KUMAR, P. Vinca alkaloids as a potential cancer therapeutics: recent update and future challenges. 3 Biotech, v. 13, n. 6, mai. 2023. DOI: https://doi.org/10.1007/s13205-023-03636-6. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC10209376/.
BARZAMAN, K.; KARAMI, J.; ZAREI, Z.; HOSSEINZADEH, A.; KAZEMI, M. H.; MORADI-KALBOLANDI, S.; SAFARI, E.; FARAHMAND, L. Breast cancer: Biology, biomarkers, and treatments. International Immunopharmacology, v. 84, 2020. DOI: https://doi.org/10.1016/j.intimp.2020.106535. Disponível em: https://www.sciencedirect.com/science/article/pii/S1567576920304768?via%3Dihub.
BRASIL. Ministério da Saúde. Tipos de câncer: mama. Instituto Nacional de Câncer José Alencar Gomes da Silva – INCA. Rio de Janeiro: MS, 2018. Disponível em: https://www.inca.gov.br/tipos-de-cancer/cancer-de-mama.
CAVALCANTE, F. P.; MILLEN, E. C.; ZERWES, F. P.; NOVITA, G. G. Progress in Local Treatment of Breast Cancer: A Narrative Review. Rev Bras Ginecol Obstet., v. 42, n. 6, p. 356-364, jun. 2020. DOI: https://doi.org/10.1055/s-0040-1712125. Disponível em: https://journalrbgo.org/article/progress-in-local-treatment-of-breastcancer-a-narrative-review/.
CHAFFER, C. L.; WEINBERG, R. A. A perspective on cancer cell metastasis. Science, v. 331, n. 6024, p. 1559–1564, 2011.
CRISCITIELLO, C.; CURIGLIANO, G. Immunotherapy of breast cancer. Progress in Tumor Research, v. 42, p. 30–43, 2015.
DAS, S.; SHARMA, R.; DIMMOCK, J. T. Synthesis and anticancer evaluation of 1,5-diaryl-3-oxo-1,4-pentadienyl analogues. Bioorganic & Medicinal Chemistry Letters, v. 30, n. 10, p. 1273-1278, 2020.
EARLY BREAST CANCER TRIALISTS’ COLLABORATIVE GROUP (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis. The Lancet, v. 378, n. 9804, p. 1707–1716, 2011.
EMENS, L. A. Breast cancer immunotherapy: facts and hopes. Clinical Cancer Research, v. 24, n. 3, p. 511–520, 2018.
FISHER, B.; ANDERSON, S.; BRYANT, J.; MARGOLESE, R. G.; DEUTSCH, M.; FISHER, E. R.; JEONG, J-H.; WOLMARK, N. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med., v. 347, n. 16, p. 1233-1241, out. 2002a. DOI: https://doi.org/10.1056/NEJMoa022152. Disponível em: https://www.nejm.org/doi/full/10.1056/NEJMoa022152.
FISZMAN, G. L.; FARIA, M. V.; NOGUEIRA, F. M. Trastuzumabe no câncer de mama: revisão dos mecanismos de resistência e estratégias terapêuticas. Revista Brasileira de Cancerologia, v. 57, n. 3, p. 425–431, 2011.
HOSSAIN, M.; DAS, S.; DAS, U.; DOROUDI, A.; ZHU, J.; DIMMOCK, J. R. Novel hybrid molecules of 3,5-bis(benzylidene)-4-piperidones and dichloroacetic acid which demonstrate potent tumour-selective cytotoxicity. Bioorganic Med Chem Lett., v. 30, n. 3, fev. 2020. DOI: https://doi.org/10.1016/j.bmcl.2019.126878
IARC – INTERNATIONAL AGENCY FOR RESEARCH ON CANCER. Cancer Today: Population Fact Sheets – Global. Lyon: WHO, 2020. Disponível em: https://gco.iarc.fr/today.
INSTITUTO NACIONAL DE CÂNCER (INCA). Estimativa 2018: incidência de câncer no Brasil. Rio de Janeiro: INCA, 2018. Disponível em: https://www.inca.gov.br/publicacoes/livros/estimativa-2018-incidencia-de-cancer-no-brasil.
INSTITUTO NACIONAL DE CÂNCER (INCA). Estimativa 2023: incidência de câncer no Brasil. Rio de Janeiro: INCA, 2022. Disponível em: https://www.inca.gov.br/publicacoes/livros/estimativa-2023-incidencia-de-cancer-no-brasil.
KLEINSIMON, S.; LONGMUSS, E.; ROLFF, J.; JÄGER, S.; EGGERT, A.; DELEBINSKI, C.; SEIFERT, G. GADD45A and CDKN1A are involved in apoptosis and cell cycle modulatory effects of viscumTT with further inactivation of the STAT3 pathway. Sci. Rep., v. 8, n. 1, abr. 2018. DOI: https://doi.org/10.1038/s41598-018-24075-x. Disponível em: https://www.nature.com/articles/s41598-018-24075-x.
KUMAR, R.; MASON, K. A. Radiation biology and treatment: Principles and clinical applications. Oncology Reports, v. 27, n. 5, p. 1234–1242, 2012.
LUIS FELIPE BUSO BORTOLOTTO, FLAVIA REGINA BARBOSA, GABRIEL SILVA, TAMIRES APARECIDA BITENCOURT, RENE OLIVEIRA BELEBONI, SEUNG JOON BAEK, MOZART MARINS, ANA LÚCIA FACHIN. Cytotoxicity of transchalcone and licochalcone A against breast cancer cells is due to apoptosis induction and cell cycle arrest. Biomedicine & Pharmacotherapy. Volume 85, 2017,Pages 425-433,ISSN 0753-3322,https://doi.org/10.1016/j.biopha.2016.11.047. (https://www.sciencedirect.com/science/article/pii/S0753332216314445)
LIVINGSTON, R. B. Principles of chemotherapy. Cancer, v. 37, n. 2 Suppl, p. 517-522, 1976.
MAADI, H. et al. Mechanisms of action and resistance to trastuzumab in HER2-positive breast cancer. Frontiers in Oncology, v. 11, p. 692614, 2021.
MAAJANI, K. et al. The global and regional burden of breast cancer in 2019: Results from the Global Burden of Disease Study 2019. BMC Public Health, v. 19, p. 1100–1110, 2019.
MANDÓ, P. et al. Mechanisms of trastuzumab action and resistance in HER2-positive breast cancer. Cancer Treatment Reviews, v. 98, p. 102223, 2021.
MASUDA, T.; JITOE, A.; ISOBE, J.; NAKATANI, N.; YONEMORI, S. Anti-oxidative and anti-inflammatory curcumin-related phenolics from rhizomes of Curcuma domestica. Phytochemistry, v. 32, n. 6, p. 1557-1560, 1993. DOI: https://doi.org/10.1016/0031-9422(93)85179-U.
MARTIN, M. et al. Bone health in patients with breast cancer: Recommendations from an expert panel. Cancer Treatment Reviews, v. 38, n. 5, p. 523–530, 2012.
MAZOUNI, C. et al. Prognostic impact of HER2 expression in early breast cancer. Breast Cancer Research and Treatment, v. 106, n. 1, p. 39–47, 2007.
MINISTÉRIO DA SAÚDE (Brasil). Protocolo Clínico e Diretrizes Terapêuticas: câncer de mama. Brasília: Ministério da Saúde, 2012.
MITOBE, Y. et al. Regulation of ESR1 and its impact on breast cancer cell proliferation. Molecular Oncology, v. 14, n. 5, p. 1230-1241, 2020.
MOHAMED, A. et al. Immunotherapy in breast cancer: Recent advances and future perspectives. Frontiers in Oncology, v. 13, p. 1241987, 2023.
MOHAMED, A. A. et al. Immunotherapy in HER2-positive breast cancer: recent advances and future directions. Breast Cancer Research and Treatment, v. 198, n. 1, p. 1-12, 2023.
MOJA, L. et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database of Systematic Reviews, n. 4, Art. No.: CD006243, 2012.
NASCIMENTO, F. S.; OTONI, C. C. Molecular classification of breast cancer. Revista Brasileira de Oncologia, v. 66, n. 1, p. 35-45, 2020.
NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2012. Disponível em: https://www.nccn.org.
NISHIMURA, F. G.; SAMPAIO, B. B.; KOMOTO, T. T.; DA SILVA, W. J.; DA COSTA, M. M. G.; HADDAD, G. I.; PERONNI, K.C.; EVANGELISTA, A. F.; HOSSAIN, M.; DIMMOCK, J. R.; BANDY, B.; BELEBONI, R. O.; MARINS, M.; FACHIN, A. L. Exploring CDKN1A Upregulation Mechanisms: Insights into Cell Cycle Arrest Induced by NC2603 Curcumin Analog in MCF-7 Breast Cancer Cells. Int J Mol Sci, v. 25, n. 9, mai. 2024a. DOI: https://doi.org/10.3390/ijms25094989. Disponível em: https://www.mdpi.com/1422-0067/25/9/4989.
NISHIMURA, F. G.; SAMPAIO, B. B; DO COUTO, G. O.; DA SILVA, A. D.; DA SILVA, W. J.; PERONNI, K. C.; EVANGELISTA, A. F.; HOSSAIN, M.; DIMMOCK, J. R.; BANDY, B.; BELEBONI, R. O.; MARINS, M.; FACHIN, A. L. The Transcriptome of BT-20 Breast Cancer Cells Exposed to Curcumin Analog NC2603 Reveals a Relationship between EGR3 Gene Modulation and Cell Migration Inhibition. Molecules, v. 29, n. 6, mar. 2024b. DOI: https://doi.org/10.3390/molecules29061366. Disponível em: https://www.mdpi.com/1420-3049/29/6/1366.
PALOMER, X. et al. GADD45A in DNA damage response and cell cycle regulation. Cell Cycle, v. 23, n. 4, p. 545-556, 2024.
PEREZ, E. A. et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2–positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. Journal of Clinical Oncology, v. 25, n. 8, p. 749–757, 2007.
PICCART-GEBHART, M. J. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New England Journal of Medicine, v. 353, n. 16, p. 1659–1672, 2005.
Rajagopal PS, Nipp RD, Selvaggi KJ. Chemotherapy for advanced cancers. Ann Palliat Med. 2014 Jul;3(3):203-28. doi: 10.3978/j.issn.2224-5820.2014.06.02. PMID: 25841696.
ROMOND, Edward H. et al.Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. The New England Journal of Medicine, Boston, v. 353, n. 16, p. 1673–1684, 2005. DOI: https://doi.org/10.1056/NEJMoa052122. Disponível em: https://www.nejm.org/doi/full/10.1056/NEJMoa052122.
SARHANGI, N.; HAJJARI, S.; HEYDARI, S. F.; GANJIZADEH, M.; ROUHOLLAH, F.; HASANZAD, M. Breast cancer in the era of precision medicine. Mol Biol Rep., v. 49, n. 10, p. 10023-10037, 2022. DOI: https://doi.org/10.1007/s11033-022-07571-2.
SEMLALI, A.; CONTANT, C.; AL-OTAIBI, B.; AL-JAMMAZ, I.; CHANDAD, F. The curcumin analog (PAC) suppressed cell survival and induced apoptosis and autophagy in oral cancer cells. Sci Rep, v. 11, 2021.
SHARMA, P.; ALLISON, J. P. The future of immune checkpoint therapy. Science, v. 348, n. 6230, p. 56–61, 2015.
SHEN Y, Fujii T, Ueno NT, Tripathy D, Fu N, Zhou H, Ning J, Xiao L. Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis. Breast Cancer Res Treat. 2019 Jan;173(1):1-9. doi: 10.1007/s10549-018-4969-6. Epub 2018 Sep 21. PMID: 30242579; PMCID: PMC6538294.
SIWAK, D. R.; SHISHODIA, S.; AGGARWAL, B. B; KURZROCK, R. Curcumininduced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IκB kinase and nuclear factor κB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer, v. 104, n. 4, p. 879-890, jul. 2005. DOI: https://doi.org/10.1002/cncr.21216.
SLAMON, DJ & Eiermann, Wolfgang & Robert, NJ & Giermek, J & Martin, Miguel & Jasiówka, Marek & Mackey, John & Chan, Arlene & Liu, M-C & Pinter, Tamas & Valero, Vicente & Falkson, C & Fornander, T & Shiftan, TA & Bensfia, S & Simon, Hitier & Bée-Munteanu, V & Drevot, P & Crown, J. (2016). Abstract S5-04: Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer. Cancer Research. 76. S5-04. 10.1158/1538-7445.SABCS15-S5-04.
SLAMON, Dennis M.D., Ph.D., Brian Leyland-Jones, M.D., Steven Shak, M.D., Hank Fuchs, M.D., Virginia Paton, Pharm.D., Alex Bajamonde, Ph.D., Thomas Fleming, Ph.D., Wolfgang Eiermann, M.D., Janet Wolter, M.D., Mark Pegram, M.D., Jose Baselga, M.D., and Larry Norton, M.D. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England Journal of Medicine, Boston, v. 344, n. 11, p. 783–792, 2001. DOI: https://doi.org/10.1056/NEJM200103153441101.
SOLOMAYER, E. F.; DIEL, I. J.; MEYBERG, G. C.; GOLLAN, C.; BASTERT, G. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat., v. 59, n. 3, p. 271-278, fev. 2000. DOI: https://doi.org/10.1023/a:1006308619659.
SONG, F.; ZHANG, L.; YU, H. X.; LU, R. R.; BAO, J. D.; TAN, C.; SUN, Z. The mechanism underlying proliferation-inhibitory and apoptosis-inducing effects of curcumin on papillary thyroid cancer cells. Food Chem., v. 132, n. 1, p. 43-50, mai. 2012. DOI: https://doi.org/10.1016/j.foodchem.2011.10.024
SUETH-SANTIAGO, V.; MENDES-SILVA, G. P.; DECOTÉ-RICARDO, D.; DE LIMA, M. E. F. Curcumina, o Pó Dourado Do Açafrão-Da-Terra: Introspecções Sobre Química e Atividades Biológicas. Quím. Nova, v. 38, n. 4, mai. 2015. DOI: https://doi.org/10.5935/0100-4042.20150035. Disponível em: https://www.scielo.br/j/qn/a/Jhxv6nxsPhPXb37fh7bgZ3t/.
UPTODATE. Systemic therapy for HER2-positive breast cancer. Disponível em: https://www.uptodate.com/contents/systemic-therapy-for-her2-positive-breast-cancer.
VERONESI, U.; CASCINELLI, N.; MARIANI, L.; GRECO, M.; SACCOZZI, R.; LUINI, A.; AGUILAR, M.; MARUBINI, E. Twenty-Year Follow-up of a Randomized Study Comparing Breast-Conserving Surgery with Radical Mastectomy for Early Breast Cancer. N Engl J Med, v. 347, n. 16, p. 1227-1232, out. 2002. DOI: https://doi.org/10.1056/NEJMoa020989.
WEIGELT, B.; PETERSE, J. L.; VAN’T VEER, L. J. Breast cancer metastasis: markers and models. Nature Reviews Cancer, v. 5, n. 8, p. 591–602, 2005.
YAO, H.; LIU, J.; XU, S.; ZHU, Z.; XU, J. The structural modification of natural products for novel drug discovery. Expert Opinion on Drug Discovery, v. 12, n. 2, p. 121-140, 2017. DOI: https://doi.org/10.1080/17460441.2016.1272757.
